Expertise in
2
conditions

Dr. Siwen Hu

Hematology
85 N Medical Dr, 
Salt Lake City, UT 
On Staff At
Accepting New Patients
Expertise in
2
conditions
85 N Medical Dr, 
Salt Lake City, UT 

Overview

Siwen Hu is a Hematologist practicing medicine in Salt Lake City, Utah.

Dr. Hu is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Melanoma, Melanoma of the Eye, Non-Small Cell Lung Cancer (NSCLC), and Neuroendocrine Tumor.

Dr. Hu is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 77 peer reviewed articles and participating in 12 clinical trials. Dr. Hu is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Hospital Affiliations

Logan Regional Hospital
University Of Utah Hospital And Clinics

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Hematology-oncology - Nielsen Rehabilitation Hospital
85 N Medical Dr, Salt Lake City, UT 84112
Other Locations
Hematology-oncology - Hci Hem-onc Clinic
1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Additional Areas of Focus

Dr. Hu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Biological
Study Drugs: Pembrolizumab, Talimogene Laherparepvec
Study Phase: Phase 2
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: October 27, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drug: FS118
Study Phase: Phase 1/Phase 2
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
Enrollment Status: Terminated
Publish Date: August 25, 2023
Intervention Type: Device, Drug
Study Phase: Phase 1
Phase Ib/II Study Combining CD24Fc With Checkpoint Inhibitors for Patients With Metastatic Melanoma
Phase Ib/II Study Combining CD24Fc With Checkpoint Inhibitors for Patients With Metastatic Melanoma
Enrollment Status: Withdrawn
Publish Date: June 01, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Study Combining an Anti-SEMA4D Antibody VX15/2503 With Checkpoint Inhibitors for Patients With Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies
Phase I Study Combining an Anti-SEMA4D Antibody VX15/2503 With Checkpoint Inhibitors for Patients With Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies
Enrollment Status: Terminated
Publish Date: April 02, 2021
Intervention Type: Biological, Other
Study Drugs: Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab
Study Phase: Phase 1
View 9 Less Clinical Trials

77 Total Publications

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Journal: bioRxiv : the preprint server for biology
Published: December 25, 2025
Similar Doctors
Expertise in
16
conditions
Dr. Narendranath Epperla
Hematology
Expertise in
16
conditions
Dr. Narendranath Epperla
Hematology

Univ. Of Utah Hosp. Im-Hematology-Hematologic

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-3229
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Narendranath Epperla is a Hematologist practicing medicine in Salt Lake City, Utah. Dr. Epperla is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Epperla is board certified in American Board Of Internal Medicine. Dr. Epperla is currently accepting new patients.

Expertise in
21
conditions
Dr. Josef Prchal
Hematology
Expertise in
21
conditions
Dr. Josef Prchal
Hematology

University Of Utah Hospital Pathology Department

50 N Medical Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-581-2507
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Josef Prchal is a Hematologist practicing medicine in Salt Lake City, Utah. Dr. Prchal is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant. Dr. Prchal is board certified in American Board Of Internal Medicine. Dr. Prchal is currently accepting new patients.

Expertise in
13
conditions
Dr. Douglas Sborov
Hematology
Expertise in
13
conditions
Dr. Douglas Sborov
Hematology

Huntsman Cancer Institute Bmt

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-2626
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Douglas Sborov is a Hematologist practicing medicine in Salt Lake City, Utah. He has been practicing medicine for over 17 years. Dr. Sborov is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Sborov is board certified in American Board Of Internal Medicine. Dr. Sborov is currently accepting new patients.

Frequently Asked Questions about Dr. Siwen Hu

How do I make an appointment with Dr. Siwen Hu?

You can book an appointment with Dr. Siwen Hu by calling their office at 801-585-0100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Siwen Hu a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Siwen Hu is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Siwen Hu specialize in?

While Dr. Siwen Hu is a Hematology, they have specific expertise in Melanoma, Melanoma of the Eye, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Siwen Hu participate in research or clinical trials?

Yes. Dr. Siwen Hu has published 77 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Siwen Hu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Siwen Hu accept my insurance?

Dr. Siwen Hu accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 801-585-0100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hu's expertise for a condition
ConditionClose
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile